Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats

Pharmacology and Toxicology

Volumn 93, Issue 1, 2003, Pages 54-56

  Gilgun Sherki, Yossi ^a   Melamed, Eldad ^a   Ziv, Ban ^a   Offen, Daniel ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; APOMORPHINE; CARBIDOPA; DEXANABINOL; GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; LAMOTRIGINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DYSKINESIA; MALE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; ROTATION; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; LEVODOPA; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUTAMATE; RILUZOLE; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 0037669360     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2003.930108.x     Document Type: Article

References (21)

1. Anaki, T., T. Kumagai, M. Matsubara, T. Ido, Y. Imai & Y. Itoyama: Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice. Metab. Brain Dis. 2000, 15, 193-201.
2. Baas, H.: Dyskinesia in Parkinson's disease. Pathophysiological and clinical risk factors. J. Neurology 2000, 247, Suppl 4, IV/12-16.
3. Barneoud, P., M. Mazadier, J. M. Miqute, S. Parmentier, P. Dubedat, A. Doble & A. Boireau: Neuroprotective effects of riluzole in a model of Parkinson's disease in the rat. Neuroscience 1996, 74, 971-983.
4. Benazzouz, A., T. Boraund, P. Dubedat, A. Boireau, J. M. Stutzmann & C. Gross: Riluzole prevents MPTP-induced Parkinsonism in the rhesus monkey: a pilot study. Eur. J. Pharmacol. 1995, 284, 299-307.
5. Bezard, E., J. M. Stutzmann, C. Imbered, T. Boraund, A. Boireau & C. Gross: Riluzole delayed appearance of Parkinsonian motor abnormalities in chronic MPTP monkey model. Eur. J. Pharmacol. 1998, 356, 101-104.
6. Boireau, A., P. Dubedat, F. Bordier, C. Peny, J. M. Miquet, G. Durand, M. Meunier & A. Doble: Riluzole and experimental Parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in trace. Neuroreport 1994, 5, 2657-2660.
7. Bryson, H. M., B. Fulton & P. Benfield: Riluzole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 1996, 52, 549-563.
8. Crossman, A. R.: A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov. Disord. 1990, 5, 100-108.
9. Davis, T. L., G. Brughitta, F. Baronti & M. M Mouradian: Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991, 41, 630-633.
10. Doble, A.: The pharmacology and mechanism of action of riluzole. Neurology 1996, 47 (Suppl 4), S233-S241.
11. Eshhar, N., S. Striem, R. Kohen, O. Tirosh & A. Biegon: Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol. 1995, 283, 19-29.
12. He, Y., A. Benz, T. Fu, M. Wang, D. F. Covey, C. F. Zorumski & S. Mennerick: Neuroprotective agent riluzole potentiates post-synaptic GABA (A) receptor function Neuropharmacology 2002, 42, 199-209.
13. Hefti, F., E. Melamed & R.J. Wurtman: The decarboxylation of DOPA in the parkinsonian brain: in vivo studies in animal models. J. Neural. Transm. 1980, Suppl. 16, 95-101.
14. Herbert, T., P. Drapeau, L. Pradier, & R. J. Dunn: Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol. Pharmacol. 1994, 45, 1055-1060.
15. Hudson, J. L., V. H. G. Craig, I Stromberg, S. Brock, J. Clayton, J. Masserano, B. J. Hoffer & G. A. Gerhardt: Correlation of apomorphine and amphetamine-induced turning with nigrostriatal dopamine content in inilateral 6-hydroxydopamine lesioned rats. Brain Res. 1993, 626, 167-174.
16. Melamed, E., F. Hefti & R. J. Wurtman: Nonaminergic striatal neurons convert exogenous L-DOPA to dopamine in Parkinsonism. Ann. Neurol. 1980, 8, 558-563.
17. Merims, D., I. Ziv, R. Djaldetti & E. Melamed: Riluzole for levodopa- induced dyskinesias in advanced Parkinson's disease. Lancet 1999, 353, 1764-1765.
18. Paxinos, G. & C. Watson: The rat brain in stereotaxic coordinate. New York Academic Press, 1986.
19. Perese, D. A., J. Ulman, J. Viola, S. E. Ewing & K. S. Bankiewicz: A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res. 1989, 494, 285-293.
20. Prakriya, M. & S. Mennerick: Selective depression of low-release probability excitatory synapses by sodium channel blockers. Neuron 2000, 26, 671-682.
21. + channels as targets for neuroprotective drugs. Trends Pharmacol. Sci. 1995, 16, 309-316.